In this phase II trial, we used the combination of @entity136 and @entity1487 ( @entity1487 ) to treat 26 @entity1 : 17 (65%) with advanced @entity788 and 9 (35%) with advanced biliary tract @entity420 (10 locally advanced and 16 metastatic); 15 (57.7%) male and 11 (42.3%) female; median age 58 (range, 39-68); median performance status 2 (range, 1-3). A total of 102 cycles were administered (median, 4 per @entity1 ). There were 8 objective responses, plus 1 complete response not confirmed by second-look laparotomy, thus the overall objective response rate was 30.7% (95% CI 12%-47%). Among the @entity1 with biliary tract @entity189 , 33% (3/9) had PR. Six (23%) @entity1 had @entity66 ( @entity66 ). All 8 responders and 3 of the @entity1 with @entity66 experienced clinical benefit (42%). The median overall survival was 9 months (range, 6-38), and the 1-year survival rate was 30%. The regimen was very well tolerated. One @entity1 developed reversible World Health Organization grade IV @entity1398 . We observed grade III @entity1398 in 11 (11%) cycles; grade III @entity882 in 7 (7%) cycles; grade III @entity33 in 7 (7%) cycles; and grade III @entity294 in 10 (10%) cycles. Asthenia grades I and II occurred in 30% of cycles and flulike syndrome grade II in 11 (11%) cycles. The combination of @entity136 and @entity1487 in @entity1 with advanced @entity788 produces promising activity and tolerability with the added potential for clinical benefit, and thus warrants further investigation.

Phase II trial of the use of XXXX and @entity1487 in the treatment of advanced @entity788 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic or biliary tract cancer', 'pancreatic adenocarcinoma'] @entity66 :: ('MESH:D004194', 'Disease') :: ['stable disease', 'SD'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU', '5-fluorouracil']
@entity136 :: (MESH:C056507,Chemical) :: ['gemcitabine']
